Arcellx Inc (ACLX) - Total Liabilities
Based on the latest financial reports, Arcellx Inc (ACLX) has total liabilities worth $201.64 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ACLX operating cash flow to assess how effectively this company generates cash.
Arcellx Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Arcellx Inc's total liabilities have evolved over time, based on quarterly financial data. Check ACLX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Arcellx Inc Competitors by Total Liabilities
The table below lists competitors of Arcellx Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NEXGEN ENERGY LTD CDI/1
F:6NEA
|
Germany | €767.98 Million |
|
NINGBO SHANSHAN GDR/A
F:OJ8
|
Germany | €22.34 Billion |
|
GDS Holdings Limited
F:G40
|
Germany | €52.26 Billion |
|
Gaztransport & Technigaz SAS
PA:GTT
|
France | €353.99 Million |
|
JBTMarel Corp
NYSE:JBTM
|
USA | $3.73 Billion |
|
Far East Smarter Energy Co Ltd
SHG:600869
|
China | CN¥17.64 Billion |
|
Morningstar Inc
NASDAQ:MORN
|
USA | $2.97 Billion |
|
MSA Safety
NYSE:MSA
|
USA | $1.19 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Arcellx Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ACLX stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arcellx Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arcellx Inc (2018–2025)
The table below shows the annual total liabilities of Arcellx Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $201.64 Million | -21.40% |
| 2024-12-31 | $256.54 Million | -24.49% |
| 2023-12-31 | $339.75 Million | +212.09% |
| 2022-12-31 | $108.86 Million | -56.51% |
| 2021-12-31 | $250.30 Million | +3399.19% |
| 2020-12-31 | $7.15 Million | -90.63% |
| 2019-12-31 | $76.33 Million | +4102.97% |
| 2018-12-31 | $1.82 Million | -- |
About Arcellx Inc
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a prod… Read more